ribavirin has been researched along with Dyspnea in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, GS; Kicska, GA; Kinahan, PE; Li, T; Liu, L; Pipavath, SNJ; Wu, W | 1 |
| Hayashi, Y; Imoto, S; Kim, CW; Kim, SK; Kim, SR | 1 |
| Brizzi, RG; da Silva Junior, AF; da Silva, AB; Garcia, E; Hota, M; Schorr, F | 1 |
| Oriñuela, I; Ortiz de Zárate, Z; Sanjuán, AZ; Velasco, J | 1 |
| Cardot-Leccia, N; Lacour, JP; Montaudié, H; Passeron, T; Sebbag, N | 1 |
| Garcia, GF; Garib, JR; Silva, Fd; Teixeira, R | 1 |
| Avendano, M; Booth, CM; Cescon, DW; Chenkin, JS; Derkach, P; Detsky, AS; Dwosh, HA; Ephtimios, IE; Gold, WL; Hawryluck, LA; Kitai, I; Matukas, LM; Mazzulli, T; Mederski, BD; Poutanen, SM; Rachlis, AR; Rea, E; Rose, DB; Shadowitz, SB; Tomlinson, GA; Walmsley, SL | 1 |
7 other study(ies) available for ribavirin and Dyspnea
| Article | Year |
|---|---|
The novel coronavirus disease (COVID-19) complicated by pulmonary embolism and acute respiratory distress syndrome.
Topics: Acute Disease; Aged; Biomarkers; Blood Platelets; Ceftazidime; COVID-19; COVID-19 Drug Treatment; Dyspnea; Fibrin Fibrinogen Degradation Products; Heparin; Humans; Hypoxia; Lung; Male; Methylprednisolone; Middle Aged; Pulmonary Embolism; Respiratory Distress Syndrome; Ribavirin; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Sudden-onset sarcoidosis with severe dyspnea developing during pegylated interferon and ribavirin combination therapy for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Dyspnea; Female; Hepatitis C, Chronic; Humans; Interferons; Polyethylene Glycols; Ribavirin; Sarcoidosis, Pulmonary | 2017 |
Bronchial casts attributed to the use of pegylated interferon and ribavirin.
Topics: Antiviral Agents; Bronchial Diseases; Calcinosis; Dyspnea; Humans; Interferons; Male; Middle Aged; Ribavirin | 2009 |
[Pericardial effusion associated to interferon in an immunocompetent patient].
Topics: Antipsychotic Agents; Antiviral Agents; Drug Therapy, Combination; Dyspnea; Hepatitis C; Humans; Immunocompetence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pericardial Effusion; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Schizophrenia | 2010 |
Drug rash with eosinophilia and systemic symptoms due to telaprevir.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antiviral Agents; Clinical Trials, Phase II as Topic; Drug Eruptions; Drug Therapy, Combination; Dyspnea; Eosinophilia; Exanthema; Female; Fever; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Transaminases; Treatment Outcome | 2010 |
Dyspnoea in patients with chronic hepatitis C treated with pegylated interferon and ribavirin.
Topics: Adult; Aged; Analysis of Variance; Antiviral Agents; Body Mass Index; Dyspnea; Female; Follow-Up Studies; Hemoglobins; Hepatitis C, Chronic; Humans; Interferon Type I; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Spirometry; Young Adult | 2011 |
Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antiviral Agents; Biomarkers; Communicable Diseases, Emerging; Comorbidity; Cough; Demography; Disease Outbreaks; Disease Progression; Dyspnea; Female; Fever; Hospitalization; Humans; Hydrocortisone; Infection Control; Intensive Care Units; Lung; Male; Middle Aged; Ontario; Proportional Hazards Models; Radiography; Respiration, Artificial; Retrospective Studies; Ribavirin; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Statistics, Nonparametric; Survival Analysis | 2003 |